Last updated: March 28, 2026
What is the Drug Associated with NDC 00955-1003?
NDC 00955-1003 corresponds to Lomitapide, a lipid-lowering agent approved by the FDA in 2012 for the treatment of homozygous familial hypercholesterolemia (HoFH). Lomitapide is marketed under the brand name Juxtapid in the United States. It functions as a microsomal triglyceride transfer protein (MTP) inhibitor, reducing low-density lipoprotein cholesterol (LDL-C).
How Large is the Market for Lomitapide?
Market Size Overview
- Estimated addressable population: 1,200 to 1,500 patients in the U.S.
- Global market size (2022): approximately $250 million.
- Growth rate (2022–2027): roughly 10% annually, driven by increased diagnosis and treatment of HoFH.
Key Market Drivers
- Rare disease designation: Lomitapide qualifies as an orphan drug.
- Diagnostic advancements: Genetic testing identifies more patients.
- Limited competition: Few approved treatments for HoFH; PCSK9 inhibitors are less effective for homozygous cases.
Market Segments
- U.S.: 600–900 patients, estimated to generate $150–200 million in 2022.
- Europe and Asia: 600–600 patients combined, contributing an additional $100 million globally.
Competitors and Alternative Treatments
| Drug Name |
Class |
Indication |
Market Share (2022) |
Price (per 30-day supply) |
| Lomitapide (Juxtapid) |
MTP inhibitor |
Homozygous FH |
70% |
$13,000–$15,000 |
| Microsomal triglyceride transfer protein (MTP) |
Same as Lomitapide |
Homozygous FH |
20% |
N/A |
| Evolocumab (Repatha) |
PCSK9 inhibitor |
Heterozygous FH, HoFH |
8% |
$5,850 per month |
| Other experimental drugs |
Various |
Rare, limited approval |
2% |
Varies |
Lomitapide dominates the rare disease market but faces competition from emerging therapies, particularly in broader lipid-lowering indications.
Price Trends and Future Projections
Current Pricing (2023)
- Average wholesale price (AWP): $13,000–$15,000 per month.
- Patient copay assistance programs: mitigate affordability barriers.
Price Trends (2023–2030)
| Year |
Projected Average Price |
Rationale |
| 2023 |
$15,000 |
Stable, with limited generic competition due to orphan designation |
| 2025 |
$15,500–$16,000 |
Slight inflation, potential early biosimilar entrants in adjacent markets |
| 2030 |
$16,000–$17,000 |
Increased manufacturing costs, potential small price increases |
Impact Factors
- Potential biosimilar entry could reduce prices by 20–30% over a decade.
- Pricing increases may be limited by payers' push for value-based agreements.
- Orphan drugs retain pricing power but face pressure from stricter reimbursement policies.
Policy and Reimbursement Environment
- Managed care organizations often require prior authorization.
- Price negotiations have begun in some European markets.
- U.S. Medicare Part D coverage applies, with cost-sharing limits impacting patient access.
Market Potential in Emerging Regions
- Asia-Pacific markets present rapid growth due to increasing genetic screening.
- Price points are expected to be 30–50% lower than U.S. levels initially.
- Regulatory pathways are evolving, with approval timelines expanding.
Key Market Risks
- Formation of biosimilars or generics could reduce prices.
- Competition from newer therapies with better safety or efficacy profiles.
- Reimbursement challenges may limit patient access, constraining revenue.
Conclusion
Lomitapide’s niche positioning in treating Homozygous FH ensures a relatively stable market with high per-unit prices. Growth prospects depend on diagnostic advances, regulatory pathways in emerging markets, and the competitive landscape. Price projections suggest modest increases driven by inflation, with potential reductions if biosimilars or generics enter the market.
Key Takeaways
- The U.S. market for Lomitapide is approximately $150–$200 million annually.
- Current prices hover around $13,000–$15,000 per month.
- Market growth is expected to be 8–10% annually, driven by increased diagnosis.
- Biosimilar and generic competition could pressure prices starting mid-2020s.
- Reimbursement and policy environments significantly influence market dynamics.
FAQs
-
What is the primary indication for NDC 00955-1003?
Homozygous familial hypercholesterolemia (HoFH).
-
How does Lomitapide compare in price to competitors?
It is significantly more expensive, with monthly costs around $13,000–$15,000, versus PCSK9 inhibitors at approximately $5,850 per month.
-
What are the main drivers of market growth?
Increased diagnosis via genetic testing and limited competition.
-
Are biosimilars likely to affect the market?
Yes. Biosimilar competition could reduce prices by 20–30% within the next decade.
-
How do reimbursement policies impact pricing?
Payers require value-based arrangements that can constrain pricing increases and improve patient access.
References
[1] U.S. Food and Drug Administration (FDA). (2012). FDA approvals: Lomitapide (Juxtapid).
[2] Grand View Research. (2022). Lipoprotein and Lipid Management Market Size, Share & Trends Analysis.
[3] IQVIA. (2022). National Prescription Audit.
[4] EvaluatePharma. (2023). Market Profiles: Rare Disease Treatments.
[5] European Medicines Agency (EMA). (2022). Market authorization data for Lomitapide.
